{"id":2403,"date":"2019-10-06T00:24:35","date_gmt":"2019-10-05T22:24:35","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2403"},"modified":"2024-06-10T10:53:24","modified_gmt":"2024-06-10T08:53:24","slug":"quimioresistencia-tumoral-i-estromal","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-moleculars-i-terapia-experimental-en-oncologia-oncobell\/quimioresistencia-tumoral-i-estromal\/","title":{"rendered":"Quimioresist\u00e8ncia tumoral i estromal"},"content":{"rendered":"\n<h1>\n\t\tQuimioresist\u00e8ncia tumoral i estromal\n\t<\/h1>\n<h3>\n\t\tResum\n\t<\/h3>\n\t<p>El nostre grup aborda diferents aspectes de la quimioresist\u00e8ncia utilitzant models animals avan\u00e7ats (orthoxenografts) i models de c\u00e8l\u00b7lules no tumorals, com els fibroblasts associats a el c\u00e0ncer, per estudiar els mecanismes de resist\u00e8ncia terap\u00e8utica en tumors s\u00f2lids i hematol\u00f2gics.<\/p>\n<p>Els orthoxenografts\u00ae s\u00f3n models experimentals de ratol\u00ed en els quals s&#8217;implanta un petit fragment de tumor hum\u00e0 (implantaci\u00f3 d&#8217;una esp\u00e8cie a una altra, xenograft) en el mateix \u00f2rgan d&#8217;origen (ortotopic). Els orthoxenografts\u00ae es caracteritzen per reproduir les caracter\u00edstiques histol\u00f2giques, gen\u00e8tiques i moleculars del tumor original primari, esdevenint una excel\u00b7lent eina cient\u00edfica per predir la resposta del pacient al tractament amb quimioterapia, i oferir alternatives de tractament basades en evid\u00e8ncies cient\u00edfiques.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h2>367<\/h2>\n<h2>Publicacions<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/04\/nacktmaus_01.jpg\" alt=\"nacktmaus_01\" itemprop=\"image\" height=\"300\" width=\"600\" title=\"nacktmaus_01\" onerror=\"this.style.display='none'\"  \/>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-0\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-0\">L\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-0\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-0\"><i>Expand<\/i><\/a>\n\t\t\t\t\tEstudi dels mecanismes gen\u00e8tics i epigen\u00e8tics associats amb l&#8217;adquisici\u00f3 de resist\u00e8ncia als tractaments de quimioter\u00e0pia en diversos tipus de tumors (Dr Villanueva)<br \/>\nEstudi de l&#8217;estroma tumoral com a modulador del creixement tumoral i de la resposta a la quimioter\u00e0pia (Dr Mollev\u00ed)<br \/>\nAvaluaci\u00f3 precl\u00ednica de nous f\u00e0rmacs amb potencial terap\u00e8utic (Drs Villanueva, Mollev\u00ed and Farr\u00e9)<br \/>\nModelatge de c\u00e0ncer hematol\u00f2gic utilitzant models de ratol\u00ed humanitzats (Dra Farr\u00e9)\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-1\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-1\">Publicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-1\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-1\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Ortiz Barahona,V;Soler,M;Davalos,V;Garcia Prieto,CA;Janin,M;Setien,F;Fernandez Rebollo,I et al, <strong>Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer<\/strong>, Mol. Cancer, 2023;22(1):83-83, doi:10.1186\/s12943-023-01785-z<\/li>\n<li>Alvarez Sierra,D;Rodriguez Grande,J;Gomez Brey,A;Bello,I;Caubet,E;Gonzalez,O;Zafon,C et al, <strong>Single cell transcriptomic analysis of Graves&#8217; disease thyroid glands reveals the broad immunoregulatory potential of thyroid follicular and stromal cells and implies a major re-interpretation of the role of aberrant HLA class II expression in autoimmunity<\/strong>, J. Autoimmun., 2023;139103072-103072, doi:10.1016\/j.jaut.2023.103072<\/li>\n<li>Pecharrom\u00e1n,I;Sol\u00e9,L;Alvarez Villanueva,D;Lobo Jarne,T;Alonso Mara\u00f1\u00f3n,J;Bertran,J; Guill\u00e9n,Y et al, <strong>I?B kinase-a coordinates BRD4 and JAK\/STAT signaling to subvert DNA damage-based anticancer therapy<\/strong>, Embo J., 2023;42(21):doi:10.15252\/embj.2023114719,<\/li>\n<li>Amirkhah,R;Gilroy,K;Malla,SB;Lannagan,TRM;Byrne,RM;Fisher,NC;Corry,SM et al, <strong>MmCMS: mouse models&#8217; consensus molecular subtypes of colorectal cancer<\/strong>., Br. J. Cancer, 2023;128(7):1333-1343, doi:10.1038\/s41416-023-02157-6<\/li>\n<li>Creus Bachiller,E;Fern\u00e1ndez Rodr\u00edguez,J;Magall\u00f3n Lorenz,M;Ortega Bertran,S;Navas Rutete,S;Romagosa,C;Silva,TM et al, <strong>Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities<\/strong>, Mol. Oncol., 2023;doi:10.1002\/1878-0261.13534<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-2\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-2\">Projectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-2\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-2\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>FIS22049. <strong>Identificaci\u00f3n de vulnerabilidades terap\u00e9uticas en c\u00e1ncer de ovario y pulm\u00f3n analizando las v\u00edas de reparaci\u00f3n del ADN por Excisi\u00f3n de Nucle\u00f3tidos (NER) y Recombinaci\u00f3n Hom\u00f3loga (HR)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 214.170\u20ac. 2023-2025. PI: Villanueva Garatachea, Alberto.<\/li>\n<li>FIS21070. <strong>Evaluaci\u00f3n espacial del impacto del tratamiento neoadyuvante sobre el microambiente tumoral en las met\u00e1stasis hep\u00e1ticas de c\u00e1ncer colorectal<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 169.400\u20ac. 2022-2024. PI: GARCIA MOLLEVI, DAVID.<\/li>\n<li>20FIS014. <strong>Genetic bases of tumor cell resitance to immune checkpoint inhibitors in orthoxenografts\/ PDOX derived from three cisplatin-based treated tumors: NSCLC, bladder and ovarian cancer<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 147.620\u20ac. 2020-2023. PI: Villanueva Garatachea, Alberto.<\/li>\n<li>FIS21065. <strong>Improving Outcomes of Patients with Extramedullary Multiple Myeloma. Potential Applicability of Orthoxenograft Models in the Study of Genetic Bases of Drug Resistance<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 135.520\u20ac. 2022-2024. PI: Farre Vallve, Maria Lourdes.<\/li>\n<li>19FIS027. <strong>Reprogramaci\u00f3n de fibroblastos asociados a carcinoma intratumorales en met\u00e1stasis hep\u00e1ticas de carcinoma colorrectal<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 111.320\u20ac. 2019-2023. PI: GARCIA MOLLEVI, DAVID.<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-3\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-3\">Transfer\u00e8ncia<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-3\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-3\"><i>Expand<\/i><\/a>\n\t\t\t\t\tLicense: PDX<br \/>\nPI: Dr. Alberto Villanueva\nLicense: PDX models 2014-2021<br \/>\nPI: Dr. Alberto Villanueva\nSpin-off: Xenopat<br \/>\nPI: Dr. Alberto Villanueva\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-4\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-4\">M\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-4\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-4\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<p>Desenvolupament de l&#8217;spin-off Xenopat<\/p>\n<p><em>Proyectos financiados por el Instituto de Salud Carlos III (ISCIII) y cofinanciados por el Fondo Europeo de Desarrollo Regional (FEDER):<\/em><\/p>\n<strong>Desarrollo \u00a0de dispersiones solidas micro\/nanoestruturadas para administraci\u00f3n oral de compuestos marinos antitumorales.<\/strong><br \/>\nIPT-2011-0754-900000<br \/>\n05\/2011-12\/2014\u00a0\u00a0\u00a0\u00a0283.488 \u20ac<br \/>\nIP: Alberto Villanueva Garatachea\n<strong>Categorizaci\u00f3n histogen\u00e9tica de orthoxenografts de C\u00e1ncer Epitelial de Ovario (CEO): Una nueva estrategia para personalizar el tratamiento de las pacientes en tiempo real<\/strong><br \/>\nPI13\/01339. 01\/2014-04\/2017. 111.500 \u20ac. IP: Alberto Villanueva Garatachea.<br \/>\nCategorizar\/estratificar el c\u00e1ncer epitelial de ovario en subgrupos de referencia en base a la histolog\u00eda y el perfil gen\u00e9tico (histogen\u00e9tica) de los diferentes orthoxenografts, u PDX ortot\u00f3picos de c\u00e1ncer de ovario, e identificar en el rat\u00f3n para cada subgrupo la mejor opci\u00f3n terap\u00e9utica.\n<strong>Identificaci\u00f3n de un &#8220;core gen\u00e9tico b\u00e1sico&#8221; asociado con la adquisici\u00f3n de resistencia al cisplatino en orthoxenografts\u00ae de tumores de pulm\u00f3n (NSCLC), epiteliales de ovario y germinales testiculares<\/strong><br \/>\nPI16\/01898. 01\/2017-12\/2019. 136.500 \u20ac. IP: Alberto Villanueva Garatachea.<br \/>\nIdentificar en tres tipos de tumores un panel m\u00ednimo de alteraciones gen\u00e9ticas espec\u00edficas asociadas con la adquisici\u00f3n de resistencia al cisplatino (&#8220;core b\u00e1sico de resistencia&#8221;) independiente del tipo de tumor. El cisplatino es el f\u00e1rmaco base del tratamiento de muchos tipos tumorales. Un porcentaje importante de los pacientes que inicialmente responden al cisplatino recaen, haci\u00e9ndose resistentes (&#8220;resistencia adquirida&#8221;), as\u00ed como existe un subgrupo de pacientes que no responden de entrada (&#8220;tumores refractarios&#8221;). A pesar de su relevancia cl\u00ednica no hay ning\u00fan marcador predictivo de respuesta\/resistencia al cisplatino que se use en la pr\u00e1ctica cl\u00ednica.\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/12\/7mUdUAq.png\" alt=\"\" width=\"249\" height=\"150\" \/><\/p>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/10\/villanueva-garatachea-alberto-150x150.jpg\" alt=\"Villanueva Garatachea, Alberto\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"villanueva-garatachea-alberto\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tVillanueva Garatachea, Alberto\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:avillanueva@idibell.cat\" title=\"avillanueva@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tavillanueva@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/10\/garcia-mollevi-david-150x150.jpg\" alt=\"garcia-mollevi-david\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"garcia-mollevi-david\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tGarcia Mollevi, David\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:dgarcia@idibell.cat\" title=\"dgarcia@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tdgarcia@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/10\/villanueva-garatachea-alberto-150x150.jpg\" alt=\"Villanueva Garatachea, Alberto\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"villanueva-garatachea-alberto\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tVillanueva Garatachea, Alberto\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:avillanueva@idibell.cat\" title=\"avillanueva@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tavillanueva@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/10\/garcia-mollevi-david-150x150.jpg\" alt=\"garcia-mollevi-david\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"garcia-mollevi-david\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tGarcia Mollevi, David\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:dgarcia@idibell.cat\" title=\"dgarcia@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tdgarcia@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2021\/05\/Untitled-1-150x150.jpg\" alt=\"Untitled-1\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Untitled-1\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tFarre Vallve, Mar\u00eda Lourdes\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:mfarre@idibell.cat\" title=\"mfarre@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tmfarre@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n<h4>\n\t\t<a href=\"http:\/\/ico.gencat.cat\/ca\/recerca\/Programa-ProCURE\/\" title=\"ProCURE\" target=\"_blank\" rel=\"noopener\">\n\t\tProCURE\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"http:\/\/xenopat.com\/\" title=\"Xenopat\" target=\"_blank\" rel=\"noopener\">\n\t\tXenopat\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/twitter.com\/Xenopat_\" title=\"@Xenopat_\" target=\"_blank\" rel=\"noopener\">\n\t\t@Xenopat_\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-0\" data-index=\"0\" aria-selected=\"true\" aria-controls=\"fl-tabs--panel-0\" aria-expanded=\"true\" role=\"tab\" tabindex=\"0\">\t\t\t\tCasp de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-1\" data-index=\"1\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-1\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-2\" data-index=\"2\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-2\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-3\" data-index=\"3\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-3\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadores\/as predoctorales\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-4\" data-index=\"4\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-4\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\tCasp de grup\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Villanueva Garatachea, Alberto<\/li>\n<li>Garcia Mollevi, David<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es principals\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Farre Vallve, Mar\u00eda Lourdes<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Ruiz Roig, N\u00faria<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadores\/as predoctorales\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Alvarez Villanueva, Daniel<\/li>\n<li>Molina Valdelvira, Natalia<\/li>\n<\/ul>\n\t\t\t\t\t\tSuport cient\u00edfic\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Calaf Sanjuanes, Monica<\/li>\n<li>Martinez Iniesta, Maria<\/li>\n<\/ul>\n<h2>\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/25423\" content=\"Es descobreix una estrat\u00e8gia terap\u00e8utica innovadora per a poder tractar el c\u00e0ncer de c\u00f2lon\" \/><meta itemprop=\"datePublished\" content=\"2024-04-12\" \/><meta itemprop=\"dateModified\" content=\"2024-04-12\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2024\/04\/Foto2_team-scaled.jpg\" \/><meta itemprop=\"width\" content=\"2560\" \/><meta itemprop=\"height\" content=\"1280\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/04\/es-descobreix-una-estrategia-terapeutica-innovadora-per-a-poder-tractar-el-cancer-de-colon\/\" title=\"Es descobreix una estrat\u00e8gia terap\u00e8utica innovadora per a poder tractar el c\u00e0ncer de c\u00f2lon\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2024\/04\/es-descobreix-una-estrategia-terapeutica-innovadora-per-a-poder-tractar-el-cancer-de-colon\/\" title=\"Es descobreix una estrat\u00e8gia terap\u00e8utica innovadora per a poder tractar el c\u00e0ncer de c\u00f2lon\">Es descobreix una estrat\u00e8gia terap\u00e8utica innovadora per a poder tractar el c\u00e0ncer de c\u00f2lon<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t12\/04\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/24617\" content=\"Un estudi de l'IDIBELL, l'ICO i l'IGTP posa la medicina de precisi\u00f3 al servei dels tumors nerviosos\" \/><meta itemprop=\"datePublished\" content=\"2023-11-23\" \/><meta itemprop=\"dateModified\" content=\"2023-11-23\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/11\/Lazaro-Villanueva-scaled.jpg\" \/><meta itemprop=\"width\" content=\"2560\" \/><meta itemprop=\"height\" content=\"1280\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/11\/un-estudi-de-lidibell-lico-i-ligtp-posa-la-medicina-de-precisio-al-servei-dels-tumors-nerviosos\/\" title=\"Un estudi de l'IDIBELL, l'ICO i l'IGTP posa la medicina de precisi\u00f3 al servei dels tumors nerviosos\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/11\/un-estudi-de-lidibell-lico-i-ligtp-posa-la-medicina-de-precisio-al-servei-dels-tumors-nerviosos\/\" title=\"Un estudi de l'IDIBELL, l'ICO i l'IGTP posa la medicina de precisi\u00f3 al servei dels tumors nerviosos\">Un estudi de l&#8217;IDIBELL, l&#8217;ICO i l&#8217;IGTP posa la medicina de precisi\u00f3 al servei dels tumors nerviosos<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t23\/11\/2023\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/24427\" content=\"Un nuevo avance en la lucha contra el c\u00e1ncer infantil\" \/><meta itemprop=\"datePublished\" content=\"2023-11-10\" \/><meta itemprop=\"dateModified\" content=\"2023-11-10\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/11\/231109-Alberto-Villanueva-copia-scaled.jpg\" \/><meta itemprop=\"width\" content=\"2560\" \/><meta itemprop=\"height\" content=\"1280\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/11\/un-nuevo-avance-en-la-lucha-contra-el-cancer-infantil\/\" title=\"Un nuevo avance en la lucha contra el c\u00e1ncer infantil\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/11\/un-nuevo-avance-en-la-lucha-contra-el-cancer-infantil\/\" title=\"Un nuevo avance en la lucha contra el c\u00e1ncer infantil\">Un nuevo avance en la lucha contra el c\u00e1ncer infantil<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t10\/11\/2023\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/24347\" content=\"Apunten a una nova combinaci\u00f3 de tractaments per combatre el c\u00e0ncer\" \/><meta itemprop=\"datePublished\" content=\"2023-10-26\" \/><meta itemprop=\"dateModified\" content=\"2023-10-26\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/10\/Villanueva-Salazar-Co.jpg\" \/><meta itemprop=\"width\" content=\"422\" \/><meta itemprop=\"height\" content=\"238\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/10\/apunten-a-una-nova-combinacio-de-tractaments-per-combatre-el-cancer\/\" title=\"Apunten a una nova combinaci\u00f3 de tractaments per combatre el c\u00e0ncer\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2023\/10\/apunten-a-una-nova-combinacio-de-tractaments-per-combatre-el-cancer\/\" title=\"Apunten a una nova combinaci\u00f3 de tractaments per combatre el c\u00e0ncer\">Apunten a una nova combinaci\u00f3 de tractaments per combatre el c\u00e0ncer<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t26\/10\/2023\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/22537\" content=\"Nous models de ratol\u00ed obren vies de recerca per a tractaments personalitzats en c\u00e0ncer d'endometri\" \/><meta itemprop=\"datePublished\" content=\"2022-11-29\" \/><meta itemprop=\"dateModified\" content=\"2022-11-29\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/11\/NP28-D-Llobet_Adv-Scie-ImatgeB.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/11\/nous-models-de-ratoli-obren-vies-de-recerca-per-a-tractaments-personalitzats-en-cancer-dendometri\/\" title=\"Nous models de ratol\u00ed obren vies de recerca per a tractaments personalitzats en c\u00e0ncer d'endometri\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/11\/nous-models-de-ratoli-obren-vies-de-recerca-per-a-tractaments-personalitzats-en-cancer-dendometri\/\" title=\"Nous models de ratol\u00ed obren vies de recerca per a tractaments personalitzats en c\u00e0ncer d'endometri\">Nous models de ratol\u00ed obren vies de recerca per a tractaments personalitzats en c\u00e0ncer d&#8217;endometri<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t29\/11\/2022\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/21505\" content=\"Descobreixen un conjunt de marcadors de mal pron\u00f2stic en pacients amb c\u00e0ncer de c\u00f2lon i recte\" \/><meta itemprop=\"datePublished\" content=\"2022-06-03\" \/><meta itemprop=\"dateModified\" content=\"2022-06-03\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/06\/NO055-Nat-Comm_IMIM-Imatge.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/06\/descobreixen-un-conjunt-de-marcadors-de-mal-pronostic-en-pacients-amb-cancer-de-colon-i-recte\/\" title=\"Descobreixen un conjunt de marcadors de mal pron\u00f2stic en pacients amb c\u00e0ncer de c\u00f2lon i recte\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/06\/descobreixen-un-conjunt-de-marcadors-de-mal-pronostic-en-pacients-amb-cancer-de-colon-i-recte\/\" title=\"Descobreixen un conjunt de marcadors de mal pron\u00f2stic en pacients amb c\u00e0ncer de c\u00f2lon i recte\">Descobreixen un conjunt de marcadors de mal pron\u00f2stic en pacients amb c\u00e0ncer de c\u00f2lon i recte<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t03\/06\/2022\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/21229\" content=\"Un estudi presenta MCLA-158, el primer candidat a f\u00e0rmac dirigit a c\u00e8l\u00b7lules mare canceroses de tumors s\u00f2lids\" \/><meta itemprop=\"datePublished\" content=\"2022-04-26\" \/><meta itemprop=\"dateModified\" content=\"2022-04-26\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/04\/NP14-R-Salazar_Nature-Medicine-Foto.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/04\/un-estudi-presenta-mcla-158-el-primer-candidat-a-farmac-dirigit-a-cellules-mare-canceroses-de-tumors-solids\/\" title=\"Un estudi presenta MCLA-158, el primer candidat a f\u00e0rmac dirigit a c\u00e8l\u00b7lules mare canceroses de tumors s\u00f2lids\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/04\/un-estudi-presenta-mcla-158-el-primer-candidat-a-farmac-dirigit-a-cellules-mare-canceroses-de-tumors-solids\/\" title=\"Un estudi presenta MCLA-158, el primer candidat a f\u00e0rmac dirigit a c\u00e8l\u00b7lules mare canceroses de tumors s\u00f2lids\">Un estudi presenta MCLA-158, el primer candidat a f\u00e0rmac dirigit a c\u00e8l\u00b7lules mare canceroses de tumors s\u00f2lids<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t26\/04\/2022\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/20578\" content=\"La generaci\u00f3 d'un model de neurofibroma a partir de c\u00e8l\u00b7lules mare obre la porta al desenvolupament de nous tractaments\" \/><meta itemprop=\"datePublished\" content=\"2022-02-22\" \/><meta itemprop=\"dateModified\" content=\"2022-02-22\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/02\/NO20-Neurofibromes-Imatge.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/02\/la-generacio-dun-model-de-neurofibroma-a-partir-de-cellules-mare-obre-la-porta-al-desenvolupament-de-nous-tractaments\/\" title=\"La generaci\u00f3 d'un model de neurofibroma a partir de c\u00e8l\u00b7lules mare obre la porta al desenvolupament de nous tractaments\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/02\/la-generacio-dun-model-de-neurofibroma-a-partir-de-cellules-mare-obre-la-porta-al-desenvolupament-de-nous-tractaments\/\" title=\"La generaci\u00f3 d'un model de neurofibroma a partir de c\u00e8l\u00b7lules mare obre la porta al desenvolupament de nous tractaments\">La generaci\u00f3 d&#8217;un model de neurofibroma a partir de c\u00e8l\u00b7lules mare obre la porta al desenvolupament de nous tractaments<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t22\/02\/2022\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/20524\" content=\"La histologia de les met\u00e0stasis hep\u00e0tiques de c\u00e0ncer de c\u00f2lon podria tenir implicaci\u00f3 en la immunoter\u00e0pia\" \/><meta itemprop=\"datePublished\" content=\"2022-02-17\" \/><meta itemprop=\"dateModified\" content=\"2022-02-17\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2022\/02\/Imatge-Mollevi.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/02\/la-histologia-de-les-metastasis-hepatiques-de-cancer-de-colon-podria-tenir-implicacio-en-la-immunoterapia\/\" title=\"La histologia de les met\u00e0stasis hep\u00e0tiques de c\u00e0ncer de c\u00f2lon podria tenir implicaci\u00f3 en la immunoter\u00e0pia\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2022\/02\/la-histologia-de-les-metastasis-hepatiques-de-cancer-de-colon-podria-tenir-implicacio-en-la-immunoterapia\/\" title=\"La histologia de les met\u00e0stasis hep\u00e0tiques de c\u00e0ncer de c\u00f2lon podria tenir implicaci\u00f3 en la immunoter\u00e0pia\">La histologia de les met\u00e0stasis hep\u00e0tiques de c\u00e0ncer de c\u00f2lon podria tenir implicaci\u00f3 en la immunoter\u00e0pia<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t17\/02\/2022\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/20009\" content=\"La medicina personalitzada, un dels pilars de l'IDIBELL\" \/><meta itemprop=\"datePublished\" content=\"2021-12-16\" \/><meta itemprop=\"dateModified\" content=\"2021-12-16\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2021\/12\/Imatge-med-personal_A_JPG.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2021\/12\/%20la-medicina-personalitzada-un-dels-pilars-de-lidibell\/\" title=\"La medicina personalitzada, un dels pilars de l'IDIBELL\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2021\/12\/%20la-medicina-personalitzada-un-dels-pilars-de-lidibell\/\" title=\"La medicina personalitzada, un dels pilars de l'IDIBELL\">La medicina personalitzada, un dels pilars de l&#8217;IDIBELL<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t16\/12\/2021\t\t\t\t\t\t\t\n\t\t<!-- .pp-content-posts -->\n\n","protected":false},"excerpt":{"rendered":"<p>Quimioresist\u00e8ncia tumoral i estromal Resum El nostre grup aborda diferents aspectes de la quimioresist\u00e8ncia utilitzant models animals avan\u00e7ats (orthoxenografts) i models de c\u00e8l\u00b7lules no tumorals, com els fibroblasts associats a el c\u00e0ncer, per estudiar els mecanismes de resist\u00e8ncia terap\u00e8utica en tumors s\u00f2lids i hematol\u00f2gics. Els orthoxenografts\u00ae s\u00f3n models experimentals de ratol\u00ed en els quals s&#8217;implanta [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-2403","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2024-11-12 10:25:45","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2403"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=2403"}],"version-history":[{"count":7,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2403\/revisions"}],"predecessor-version":[{"id":25907,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2403\/revisions\/25907"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=2403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}